The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes

Stacy V. Smith, Deborah I. Friedman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension-associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014. Background: Prior to the IIHTT, clinicians managed idiopathic intracranial hypertension based on data from small, unmasked trials, expert opinion, and clinical experience. Due to the lack of empiric evidence, there were no official treatment protocols to guide treatment of the disorder. Methods: We performed a PubMed literature search for all articles with data from the IIHTT Study Group. After review of each article and any relevant supporting literature, the results were compiled into a summary of the literature. Results: The PubMed search identified 14 articles with primary and/or secondary outcome data from the IIHTT. We summarized the findings for the primary outcome of visual field outcomes in the acetazolamide treatment group compared to the placebo group, as well as secondary outcomes for the safety and tolerability of acetazolamide, cerebrospinal fluid opening pressure, quality of life, fundus photography, and optical coherence tomography. While both groups demonstrated improvement on most outcomes, acetazolamide had a greater effect even when controlling for its effect on weight loss. Conclusions: As the first large, randomized, prospective trial, the IIHTT extensively expanded the available data on idiopathic intracranial hypertension treatment. Most importantly, it provided support for the safe use of acetazolamide up to 4 g daily with weight loss for effective treatment of mild vision loss in IIH, with associated improvements in papilledema, increased intracranial pressure, and quality of life.

Original languageEnglish (US)
Pages (from-to)1303-1310
Number of pages8
JournalHeadache
Volume57
Issue number8
DOIs
StatePublished - Sep 1 2017

Fingerprint

Pseudotumor Cerebri
Acetazolamide
Therapeutics
Weight Loss
PubMed
Quality of Life
Cerebrospinal Fluid Pressure
Papilledema
Photography
Optical Coherence Tomography
Intracranial Pressure
Expert Testimony
Clinical Protocols
Visual Fields
Multicenter Studies
Placebos

Keywords

  • acetazolamide
  • automated perimetry
  • idiopathic intracranial hypertension
  • optical coherence tomography
  • pseudotumor cerebri
  • vision loss

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The Idiopathic Intracranial Hypertension Treatment Trial : A Review of the Outcomes. / Smith, Stacy V.; Friedman, Deborah I.

In: Headache, Vol. 57, No. 8, 01.09.2017, p. 1303-1310.

Research output: Contribution to journalArticle

@article{bc1295785d534e1fab55ef6bf4c7727b,
title = "The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes",
abstract = "Objective: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension-associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014. Background: Prior to the IIHTT, clinicians managed idiopathic intracranial hypertension based on data from small, unmasked trials, expert opinion, and clinical experience. Due to the lack of empiric evidence, there were no official treatment protocols to guide treatment of the disorder. Methods: We performed a PubMed literature search for all articles with data from the IIHTT Study Group. After review of each article and any relevant supporting literature, the results were compiled into a summary of the literature. Results: The PubMed search identified 14 articles with primary and/or secondary outcome data from the IIHTT. We summarized the findings for the primary outcome of visual field outcomes in the acetazolamide treatment group compared to the placebo group, as well as secondary outcomes for the safety and tolerability of acetazolamide, cerebrospinal fluid opening pressure, quality of life, fundus photography, and optical coherence tomography. While both groups demonstrated improvement on most outcomes, acetazolamide had a greater effect even when controlling for its effect on weight loss. Conclusions: As the first large, randomized, prospective trial, the IIHTT extensively expanded the available data on idiopathic intracranial hypertension treatment. Most importantly, it provided support for the safe use of acetazolamide up to 4 g daily with weight loss for effective treatment of mild vision loss in IIH, with associated improvements in papilledema, increased intracranial pressure, and quality of life.",
keywords = "acetazolamide, automated perimetry, idiopathic intracranial hypertension, optical coherence tomography, pseudotumor cerebri, vision loss",
author = "Smith, {Stacy V.} and Friedman, {Deborah I.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/head.13144",
language = "English (US)",
volume = "57",
pages = "1303--1310",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The Idiopathic Intracranial Hypertension Treatment Trial

T2 - A Review of the Outcomes

AU - Smith, Stacy V.

AU - Friedman, Deborah I.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension-associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014. Background: Prior to the IIHTT, clinicians managed idiopathic intracranial hypertension based on data from small, unmasked trials, expert opinion, and clinical experience. Due to the lack of empiric evidence, there were no official treatment protocols to guide treatment of the disorder. Methods: We performed a PubMed literature search for all articles with data from the IIHTT Study Group. After review of each article and any relevant supporting literature, the results were compiled into a summary of the literature. Results: The PubMed search identified 14 articles with primary and/or secondary outcome data from the IIHTT. We summarized the findings for the primary outcome of visual field outcomes in the acetazolamide treatment group compared to the placebo group, as well as secondary outcomes for the safety and tolerability of acetazolamide, cerebrospinal fluid opening pressure, quality of life, fundus photography, and optical coherence tomography. While both groups demonstrated improvement on most outcomes, acetazolamide had a greater effect even when controlling for its effect on weight loss. Conclusions: As the first large, randomized, prospective trial, the IIHTT extensively expanded the available data on idiopathic intracranial hypertension treatment. Most importantly, it provided support for the safe use of acetazolamide up to 4 g daily with weight loss for effective treatment of mild vision loss in IIH, with associated improvements in papilledema, increased intracranial pressure, and quality of life.

AB - Objective: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension-associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014. Background: Prior to the IIHTT, clinicians managed idiopathic intracranial hypertension based on data from small, unmasked trials, expert opinion, and clinical experience. Due to the lack of empiric evidence, there were no official treatment protocols to guide treatment of the disorder. Methods: We performed a PubMed literature search for all articles with data from the IIHTT Study Group. After review of each article and any relevant supporting literature, the results were compiled into a summary of the literature. Results: The PubMed search identified 14 articles with primary and/or secondary outcome data from the IIHTT. We summarized the findings for the primary outcome of visual field outcomes in the acetazolamide treatment group compared to the placebo group, as well as secondary outcomes for the safety and tolerability of acetazolamide, cerebrospinal fluid opening pressure, quality of life, fundus photography, and optical coherence tomography. While both groups demonstrated improvement on most outcomes, acetazolamide had a greater effect even when controlling for its effect on weight loss. Conclusions: As the first large, randomized, prospective trial, the IIHTT extensively expanded the available data on idiopathic intracranial hypertension treatment. Most importantly, it provided support for the safe use of acetazolamide up to 4 g daily with weight loss for effective treatment of mild vision loss in IIH, with associated improvements in papilledema, increased intracranial pressure, and quality of life.

KW - acetazolamide

KW - automated perimetry

KW - idiopathic intracranial hypertension

KW - optical coherence tomography

KW - pseudotumor cerebri

KW - vision loss

UR - http://www.scopus.com/inward/record.url?scp=85026444621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026444621&partnerID=8YFLogxK

U2 - 10.1111/head.13144

DO - 10.1111/head.13144

M3 - Article

C2 - 28758206

AN - SCOPUS:85026444621

VL - 57

SP - 1303

EP - 1310

JO - Headache

JF - Headache

SN - 0017-8748

IS - 8

ER -